Clinical trials: Non-cystic Fibrosis Bronchiectasis
Bronchiectasis
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14…
- Trial name
- RESPIRE 2 (NCT02106832)
- Testing
- Ciprofloxacin (BAYQ3939) dry powder for inhalation
- Where
- 207 sites in United States, Argentina and 23 more
- Volunteers
- 521 people
- Sponsor
- Bayer
Bronchiectasis, Lower Respiratory Infection
Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.
To test whether POL7080 is effective in patients with exacerbation of non-cystic fibrosis bronchiectasis caused by Pseudomonas aeruginosa infection.
- Trial name
- NCT02096315
- Testing
- POL7080
- Where
- 4 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Polyphor Ltd.
Bronchiectasis
Exercise Capacity in Patients With Cystic Fibrosis vs. Non-cystic Fibrosis Bronchiectasis
Introduction: Bronchiectasis is a chronic lung disease in which the underlying condition causes permanent damage to the conducting airways. Bronchiectasis is associated with considerable morbidity and poor quality of life.
- Trial name
- NCT03147651
- Where
- Israel
- Volunteers
- 119 people
- Sponsor
- Rambam Health Care Campus
Bronchiectasis
Study of Bronchiectasis and Associated Cardiovascular Comorbidities
Effect of cardiovascular comorbidities on disease severity and quality of life in Patients with acute exacerbation of non-cystic fibrosis bronchiectasis
- Trial name
- NCT05783869
- Testing
- Echocardiography
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Bronchiectasis
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14…
- Trial name
- RESPIRE 1 (NCT01764841)
- Testing
- Ciprofloxacin DPI (BAYQ3939)
- Where
- 151 sites in United States, Argentina and 12 more
- Volunteers
- 416 people
- Sponsor
- Bayer
Non-cystic Fibrosis Bronchiectasis, Healthy
The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis
Non-cystic fibrosis bronchiectasis patients (and controls) were recruited for the study. The investigators' aim was to study the relevance of clinical parameters in terms of underlying disease severity, proteolysis and…
- Trial name
- NCT01792440
- Where
- Belgium
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Bronchiectasis
A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis
The investigators hypothesise that long term statin treatment will improve patients' symptoms through its anti-inflammatory effect.
- Trial name
- NCT01299181
- Testing
- Atorvastatin
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Edinburgh
Non-Cystic Fibrosis Bronchiectasis, Cystic Fibrosis
A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects
Human Neutrophil Elastase (HNE) plays a pivotal role in innate immunity and in neutrophilic lung inflammation that characterized many diseases.
- Trial name
- CHF6333 FIH (NCT03056326)
- Testing
- CHF6333 (Part 1 - SAD), CHF6333 (Part 2 - MAD)
- Where
- Belgium
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Non-cystic Fibrosis Bronchiectasis
Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis
Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight.
- Trial name
- NCT05743946
- Testing
- Trikafta
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Emory University
Non-cystic Fibrosis Bronchiectasis
A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.
- Trial name
- NCT06660992
- Testing
- HSK31858, tablet
- Where
- 2 sites in China
- Volunteers
- 669 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Bronchiectasis
Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis
The primary objective of this study is to assess the safety and tolerability of 28 day oral administration of BAY85-8501 versus placebo in subjects with non-CF Bronchiectasis (BE).
- Trial name
- NCT01818544
- Testing
- BAY85-8501
- Where
- 33 sites in France, Germany and 3 more
- Volunteers
- 94 people
- Sponsor
- Bayer
Bronchiectasis Adult, Yoga
Effects of an Online Yoga Program on Exercise Capacity and Quality of Life in Bronchiectasis Patients
Bronchiectasis is a chronic lung disease characterized by persistent cough, sputum production, shortness of breath, and recurrent infections, which can reduce physical capacity and quality of life.
- Trial name
- YOGA-BR (NCT07540936)
- Testing
- Yoga Program
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Istanbul Medipol University Hospital
Non-cystic Fibrosis Bronchiectasis
Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough
This is a randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety and efficacy of ARINA-1 compared to placebo (isotonic saline, 0.9%) in participants with NCFBE.
- Trial name
- NCT05495243
- Testing
- ARINA-1
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Renovion, Inc.
Bronchiectasis
Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?
Bronchiectasis is a chronic chest condition which causes a persistent cough and frequent chest infections. One of the main forms of treatment is chest physiotherapy.
- Trial name
- NCT00816309
- Testing
- Acapella Physiotherapy
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- NHS Lothian
Non-cystic Fibrosis Bronchiectasis (NCFBE)
Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Renal Impairment
The study is being conducted to compare the pharmacokinetics, safety of HSK31858 in subjects with mild, moderate, severe renal impairment and normal renal function.
- Trial name
- NCT07915011
- Testing
- HSK31858 tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Bronchiectasis, Bronchiectasis With Acute Exacerbation
A Pilot Study to Evaluate the Use of the Vest® System for Treatment of Bronchiectasis Patients in the Home Setting
This a 70 patient multi-site non blinded randomized control trial evaluating the use of the Vest® System for treatment of Non-Cystic Fibrosis Bronchiectasis (NCFBE) patients in the home setting.
- Trial name
- NCT04017312
- Testing
- High Frequency Chest Wall Oscillation, Oscillating Positive Expiratory Pressure (OPEP)
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Hill-Rom
BRONCHIECTASIS
Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa
Statins are a class of drug used to prevent heart attacks and strokes by lowering blood cholesterol levels. They have also been found to have a beneficial "side effect" of lowering the level of inflammation in the body.
- Trial name
- NCT01299194
- Testing
- ATORVASTATIN
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University of Edinburgh
Bronchiectasis
Sputum Clearance Effects of Hypertonic Saline in Non-cystic Fibrosis Bronchiectasis
This study aims to analyze whether the hypertonic saline nebulization enhances sputum clearance effects, reduces the impact on cough severity and their level of safety and tolerability in a population with non-cystic fibrosis…
- Trial name
- NCT02392663
- Testing
- Hypertonic saline solution, Hyaneb solution, Isotonic saline solution
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Hospital Clinic of Barcelona
Non-cystic Fibrosis Bronchiectasis
Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis
This non-randomised open-label prospective pilot study evaluates the safety and efficacy of inhalations of ultra-low doses of alkylating drug melphalan for the treatment of non-cystic fibrosis bronchiectasis.
- Trial name
- SEADIB1 (NCT04278040)
- Testing
- Melphalan
- Where
- Russia
- Volunteers
- 7 people
- Sponsor
- Federal State Budgetary Institution, Pulmonology Scientific Research Institute
Non-Cystic Fibrosis Bronchiectasis
Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)
A Phase 1/2a, Multi-Centre, Randomised, Open-label study to assess the safety, tolerability, PK, and efficacy of RESP30X in Adult NCFB participants with confirmed high-titre respiratory PPMs.
- Trial name
- NOPA (NCT06663176)
- Testing
- RESP302, RESP303
- Where
- Ukraine
- Volunteers
- 60 people
- Sponsor
- Thirty Respiratory Limited